AP2498A - Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol - Google Patents

Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Info

Publication number
AP2498A
AP2498A AP2009004870A AP2009004870A AP2498A AP 2498 A AP2498 A AP 2498A AP 2009004870 A AP2009004870 A AP 2009004870A AP 2009004870 A AP2009004870 A AP 2009004870A AP 2498 A AP2498 A AP 2498A
Authority
AP
ARIPO
Prior art keywords
alpha
beta
quinolineethanol
naphthalenyl
dimethylamino
Prior art date
Application number
AP2009004870A
Other languages
English (en)
Other versions
AP2009004870A0 (en
Inventor
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Yolande Lydia Lang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2498(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AP2009004870A0 publication Critical patent/AP2009004870A0/xx
Application granted granted Critical
Publication of AP2498A publication Critical patent/AP2498A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2009004870A 2006-12-05 2007-12-03 Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol AP2498A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (2)

Publication Number Publication Date
AP2009004870A0 AP2009004870A0 (en) 2009-06-30
AP2498A true AP2498A (en) 2012-10-19

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004870A AP2498A (en) 2006-12-05 2007-12-03 Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Country Status (34)

Country Link
US (1) US8546428B2 (da)
EP (1) EP2086940B1 (da)
JP (2) JP2010511663A (da)
KR (1) KR101514700B1 (da)
CN (2) CN105012303A (da)
AP (1) AP2498A (da)
AR (1) AR064149A1 (da)
AU (1) AU2007328945B2 (da)
BR (1) BRPI0719693A2 (da)
CA (1) CA2668512C (da)
CL (1) CL2007003472A1 (da)
CY (1) CY1113594T1 (da)
DK (1) DK2086940T3 (da)
EA (1) EA017091B9 (da)
ES (1) ES2387923T3 (da)
HK (1) HK1214513A1 (da)
HR (1) HRP20120639T1 (da)
IL (1) IL199077A (da)
JO (1) JO2973B1 (da)
ME (1) ME01456B (da)
MX (1) MX2009005909A (da)
MY (1) MY148844A (da)
NO (1) NO342773B1 (da)
NZ (1) NZ576485A (da)
PE (1) PE20081350A1 (da)
PL (1) PL2086940T3 (da)
PT (1) PT2086940E (da)
RS (1) RS52408B (da)
SI (1) SI2086940T1 (da)
TW (1) TWI417098B (da)
UA (1) UA97813C2 (da)
UY (1) UY30762A1 (da)
WO (1) WO2008068231A1 (da)
ZA (1) ZA200903907B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
EP3250182B1 (en) * 2015-01-27 2023-04-26 Janssen Pharmaceutica NV Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
KR102106318B1 (ko) * 2015-10-20 2020-05-06 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 베다퀼린 푸마레이트의 결정형 및 그의 제조방법
LT3487851T (lt) * 2016-07-20 2021-12-27 Novartis Ag Aminopiridino dariniai ir jų naudojimas kaip selektyvių alk-2 inhibitorių
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JP2001503411A (ja) 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー,ユー.エス.ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY, 14 May 2005 (2005-05-14), XP002433954, accession no. 845533-86-0, abstract *

Also Published As

Publication number Publication date
MX2009005909A (es) 2009-06-16
CY1113594T1 (el) 2016-06-22
CN105012303A (zh) 2015-11-04
TWI417098B (zh) 2013-12-01
JP2015028049A (ja) 2015-02-12
EP2086940B1 (en) 2012-05-16
US8546428B2 (en) 2013-10-01
ME01456B (me) 2014-04-20
EA200970532A1 (ru) 2009-10-30
IL199077A (en) 2016-09-29
SI2086940T1 (sl) 2012-09-28
HRP20120639T1 (hr) 2012-08-31
AP2009004870A0 (en) 2009-06-30
NZ576485A (en) 2012-01-12
JP2010511663A (ja) 2010-04-15
EA017091B9 (ru) 2014-10-30
WO2008068231A1 (en) 2008-06-12
NO342773B1 (no) 2018-08-06
CL2007003472A1 (es) 2008-08-22
BRPI0719693A2 (pt) 2013-12-24
JO2973B1 (en) 2016-03-15
DK2086940T3 (da) 2012-08-20
CA2668512C (en) 2015-03-24
PE20081350A1 (es) 2008-09-18
TW200838527A (en) 2008-10-01
MY148844A (en) 2013-06-14
PL2086940T3 (pl) 2012-10-31
UY30762A1 (es) 2008-07-03
CA2668512A1 (en) 2008-06-12
NO20092535L (no) 2009-08-06
ES2387923T3 (es) 2012-10-04
EA017091B1 (ru) 2012-09-28
RS52408B (en) 2013-02-28
HK1214513A1 (zh) 2016-07-29
ZA200903907B (en) 2013-08-28
AR064149A1 (es) 2009-03-18
UA97813C2 (uk) 2012-03-26
KR20090087020A (ko) 2009-08-14
EP2086940A1 (en) 2009-08-12
KR101514700B1 (ko) 2015-04-24
US20100028428A1 (en) 2010-02-04
AU2007328945B2 (en) 2014-04-03
AU2007328945A1 (en) 2008-06-12
CN101547904A (zh) 2009-09-30
JP5894239B2 (ja) 2016-03-23
PT2086940E (pt) 2012-08-09

Similar Documents

Publication Publication Date Title
AP2498A (en) Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
EP1986699A4 (en) RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE
EP2046259A4 (en) PATIENTS LIEGE
GB0610680D0 (en) Therapeutic compounds
IL193678A0 (en) Therapeutic compounds
GB0603041D0 (en) Therapeutic compounds
IL193102A0 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
HK1203925A1 (en) Therapeutic compounds
GB0606663D0 (en) Therapeutic compounds
GB0615809D0 (en) Therapeutic compounds
GB0612971D0 (en) Therapeutic compounds
GB0625349D0 (en) Therapeutic compounds
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
GB0625345D0 (en) Therapeutic compounds
GB0605573D0 (en) Therapeutic Compounds
GB0603455D0 (en) Therapeutic compounds
IL205752A0 (en) Octahydroquinolizines for antidiabetic treatment
IL188897A0 (en) 3-(2-(dimethylamino)methyl(cyclohex
GB0608269D0 (en) Therapeutic compounds
GB2439923B (en) Therapeutic compounds
ITMI20060760A1 (it) Procedimento per il trattamento di tessuti
AU312984S (en) Headgear for patient interface
AU312983S (en) Headgear for patient interface
GB0611498D0 (en) Therapeutic compounds
GB0615907D0 (en) Therapeutic Compounds